{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:38:24Z","timestamp":1759451904935,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.vaccine.2021.01.047","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T20:20:24Z","timestamp":1611865224000},"page":"1257-1264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge"],"prefix":"10.1016","volume":"39","author":[{"given":"Michal","family":"Krolik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Csepregi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Engetschwiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.01.047_b0005","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1128\/jvi.68.11.7367-7373.1994","article-title":"Virus-induced immunosuppression: kinetic analysis of the selection of a mutation associated with viral persistence","volume":"68","author":"Evans","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0010","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1128\/jvi.65.4.1863-1869.1991","article-title":"Molecular basis of viral persistence: a single amino acid change in the glycoprotein of lymphocytic choriomeningitis virus is associated with suppression of the antiviral cytotoxic T-lymphocyte response and establishment of persistence","volume":"65","author":"Salvato","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0015","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1084\/jem.192.9.1249","article-title":"Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells","volume":"192","author":"Sevilla","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.01.047_b0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1084\/jem.160.2.521","article-title":"Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice: Role in suppression of cytotoxic T lymphocyte response and viral persistence","volume":"160","author":"Ahmed","year":"1984","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.01.047_b0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.1235214","article-title":"Persistent LCMV infection is controlled by blockade of type I interferon signaling","volume":"340","author":"Teijaro","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2021.01.047_b0030","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa053240","article-title":"Transmission of Lymphocytic Choriomeningitis Virus by Organ Transplantation","volume":"354","author":"Fischer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.01.047_b0035","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/archpedi.1996.02170290106019","article-title":"Congenital lymphocytic choriomeningitis virus infection","volume":"150","author":"Barton","year":"1996","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2021.01.047_b0040","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1371\/journal.ppat.0030149","article-title":"Congenital viral infections of the brain: Lessons learned from lymphocytic choriomeningitis virus in the neonatal rat","volume":"3","author":"Bonthius","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.01.047_b0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1126\/science.271.5246.173","article-title":"Immunology taught by viruses","volume":"271","author":"Zinkernagel","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2021.01.047_b0050","doi-asserted-by":"crossref","unstructured":"N J, Homola a M, Muller U, Steinhoff U, Reis LFL, Hemmi S, et al. Functional Role of Type I and Type 11 Interferons in Antiviral Defense 1994;264:10\u20133. https:\/\/doi.org\/10.1126\/science.8009221.","DOI":"10.1126\/science.8009221"},{"key":"10.1016\/j.vaccine.2021.01.047_b0055","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0060","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O","article-title":"Virus-specific MHC class II-restricted TCR-transgenic mice: Effects on humoral and cellular immune responses after viral infection","volume":"28","author":"Oxenius","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.01.047_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2017.07.012","article-title":"Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations","volume":"25","author":"Wingerath","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2021.01.047_b0075","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.4049\/jimmunol.1103656","article-title":"Differential Roles for RIG-I\u2013like Receptors and Nucleic Acid-Sensing TLR Pathways in Controlling a Chronic Viral Infection","volume":"188","author":"Clingan","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0080","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/JVI.01331-07","article-title":"Cellular Entry of Lymphocytic Choriomeningitis Virus","volume":"82","author":"Rojek","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.virol.2004.01.033","article-title":"Does Toll-like receptor 3 play a biological role in virus infections?","volume":"322","author":"Edelmann","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2021.01.047_b0090","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20050821","article-title":"Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection","volume":"202","author":"Kolumam","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.01.047_b0095","doi-asserted-by":"crossref","unstructured":"M\u00fcller U, Steinhoff U, Reis LFL, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science (80-) 1994;264:1918\u201321. https:\/\/doi.org\/10.1126\/science.8009221.","DOI":"10.1126\/science.8009221"},{"key":"10.1016\/j.vaccine.2021.01.047_b0100","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","article-title":"Type I Interferon in Chronic Virus Infection and Cancer","volume":"38","author":"Snell","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0105","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1128\/jvi.68.3.1951-1955.1994","article-title":"Resistance of lymphocytic choriomeningitis virus to alpha\/beta interferon and to gamma interferon","volume":"68","author":"Moskophidis","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0110","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.1128\/JVI.75.18.8407-8423.2001","article-title":"Critical Role for Alpha\/Beta and Gamma Interferons in Persistence of Lymphocytic Choriomeningitis Virus by Clonal Exhaustion of Cytotoxic T Cells","volume":"75","author":"Ou","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0115","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1128\/jvi.69.8.4792-4796.1995","article-title":"Antiviral defense in mice lacking both alpha\/beta and gamma interferon receptors","volume":"69","author":"van den Broek","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0120","doi-asserted-by":"crossref","unstructured":"Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KCF, Welch M, et al. Persistent LCMV infection is controlled by blockade of type 1 interferon signaling. Science (80-) 2013;340:207\u201311. https:\/\/doi.org\/10.1126\/science.1235214.","DOI":"10.1126\/science.1235214"},{"key":"10.1016\/j.vaccine.2021.01.047_b0125","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.4049\/jimmunol.176.8.4525","article-title":"CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion","volume":"176","author":"Aichele","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis"},{"key":"10.1016\/j.vaccine.2021.01.047_b0135","unstructured":"Stanley P, Walter O, Paul O. Vaccines. 6th Editio. 2012."},{"key":"10.1016\/j.vaccine.2021.01.047_b0140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-1-4939-3387-7_17","article-title":"Reverse genetics approaches to control arenavirus","volume":"1403","author":"Mart\u00ednez-Sobrido","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0145","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1128\/JVI.03401-14","article-title":"Development of Live-Attenuated Arenavirus Vaccines Based on Codon Deoptimization","volume":"89","author":"Cheng","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0150","doi-asserted-by":"crossref","first-page":"7373","DOI":"10.1128\/JVI.00307-15","article-title":"Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines","volume":"89","author":"Cheng","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0155","doi-asserted-by":"crossref","DOI":"10.3791\/50662-v","article-title":"Generation of recombinant arenavirus for vaccine development in FDA-approved Vero cells","author":"Cheng","year":"2013","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2021.01.047_b0160","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1073\/pnas.0600652103","article-title":"Recovery of an arenavirus entirely from RNA polymerase I\/II-driven cDNA","volume":"103","author":"Flatz","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2021.01.047_b0165","article-title":"Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection","author":"Sommerstein","year":"201511","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.01.047_b0170","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1128\/JVI.00236-14","article-title":"Evolution of Recombinant Lymphocytic Choriomeningitis Virus\/Lassa Virus In Vivo Highlights the Importance of the GPC Cytosolic Tail in Viral Fitness","volume":"88","author":"Sommerstein","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.01.047_b0175","doi-asserted-by":"crossref","DOI":"10.1126\/science.1235208","article-title":"Blockade of chronic type I interferon signaling to control persistent LCMV infection","author":"Wilson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2021.01.047_b0180","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.chom.2015.04.005","article-title":"Blockade of interferon beta, but not interferon alpha, signaling controls persistent viral infection","volume":"17","author":"Ng","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2021.01.047_b0185","doi-asserted-by":"crossref","unstructured":"Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection 2005;202:637\u201350. https:\/\/doi.org\/10.1084\/jem.20050821.","DOI":"10.1084\/jem.20050821"},{"key":"10.1016\/j.vaccine.2021.01.047_b0190","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.immuni.2014.05.003","article-title":"Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1","volume":"40","author":"Crouse","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2021.01.047_b0195","doi-asserted-by":"crossref","unstructured":"Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science (80-) 2013;340:202\u20137. https:\/\/doi.org\/10.1126\/science.1235208.","DOI":"10.1126\/science.1235208"},{"key":"10.1016\/j.vaccine.2021.01.047_b0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1399-3062.2007.00232.x","article-title":"Suppression of cell-mediated immunity by a donor-transmitted lymphocytic choriomeningitis virus in a kidney transplant recipient","volume":"9","author":"Gautam","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.047_b0205","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa073785","article-title":"A new arenavirus in a cluster of fatal transplant-associated diseases","volume":"358","author":"Palacios","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.01.047_b0210","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3201\/eid2309.170775","article-title":"Microcephaly caused by lymphocytic choriomeningitis virus","volume":"23","author":"Delaine","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2021.01.047_b0215","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0166-0934(91)90018-U","article-title":"Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates","volume":"33","author":"Battegay","year":"1991","journal-title":"J Virol Methods"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21000748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21000748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:53:15Z","timestamp":1759402395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21000748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0264410X21000748"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}